Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093350 · ClinicalTrials.gov registry record · Phase 2
TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
A Phase 2 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03093350 is a Phase 2 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 12 participants.
The verdict
NCT03093350, a Phase 2 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Status - CLOSED TO PATIENT ENROLLMENT (CNPE) The study is being conducted in patients in which breast cancer has come back after standard treatment. Volunteers in this research study are treated using special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy. The proteins that investigators are targeting in this study are called tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They do not show, or they show up in low quantities, on normal human cells. In this study, investigators target five common TAAs. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2. On a different study, patients have been treated and so far this treatment has shown to be safe. Investigators now want to try this treatment in patients with breast cancer. These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to determine the clinical efficacy of TAA-specific CTLs, to learn what the side-effects are, and to see whether this therapy might help patients with breast cancer.
Interventions
- BIOLOGICAL TAA-specific CTLs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2024-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03093350
The ClinicalTrials.gov registry entry for NCT03093350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAA-specific CTLs is the first listed.
NCT03093350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03093350 about?
NCT03093350 is a clinical study titled "TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer". Status - CLOSED TO PATIENT ENROLLMENT (CNPE) The study is being conducted in patients in which breast cancer has come back after standard treatment. Volunteers in this research study are treated using special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes...
What is the current status of trial NCT03093350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-10-10. Estimated completion is 2024-08-23.
What interventions are being tested in trial NCT03093350?
The interventions under investigation include: TAA-specific CTLs (BIOLOGICAL).
Who is sponsoring clinical trial NCT03093350?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.